Preferred Label : Beremagene Geperpavec;
UNII : AQN7K24KQU;
CAS number : 2241888-62-8;
Molecule name : KB-103;
NCI Metathesaurus CUI : CL1411919;
Origin ID : C174623;
UMLS CUI : C5420879;
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
concept_is_in_subset
https://ansm.sante.fr/tableau-acces-derogatoire/vyjuvek
2025
false
false
false
France
French
insurance, health, reimbursement
Beremagene Geperpavec
beremagene geperpavec
drug information
continuity of patient care
guidelines for drug use
administration, cutaneous
epidermolysis bullosa dystrophica
epidermolysis bullosa dystrophica
infant
child
COL7A1 Gene Mutation
summary of product characteristics
package leaflet
gene therapy
infant, newborn
---
https://www.has-sante.fr/jcms/p_3689626/fr/vyjuvek-beremagene-geperpavec-epidermolyse-bulleuse-dystrophique
2025
false
false
false
France
insurance, health, reimbursement
Beremagene Geperpavec
beremagene geperpavec
COL7A1 Gene Mutation
Gene Therapy Agents
evaluation of the transparency committee
epidermolysis bullosa dystrophica
---
https://www.has-sante.fr/jcms/p_3543140/fr/b-vec-beremagene-geperpavec-epidermolyse-bulleuse-dystrophique
2024
false
false
false
France
Beremagene Geperpavec
beremagene geperpavec
genetic therapy
gene therapy
wounds
treatment outcome
insurance, health, reimbursement
biological products
mutation
COL7A1 Gene Mutation
infant
child
adolescent
adult
administration, cutaneous
collagen type VII, alpha1 subunit
evaluation of the transparency committee
epidermolysis bullosa dystrophica
---
https://ansm.sante.fr/tableau-acces-derogatoire/beremagene-geperpavec
2024
false
false
false
France
French
Beremagene Geperpavec
beremagene geperpavec
summary of product characteristics
package leaflet
guidelines for drug use
genetic therapy
gene therapy
biological products
epidermolysis bullosa dystrophica
infant
child
adolescent
adult
wounds
mutation
COL7A1 Gene Mutation
---